<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415298</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000520463</org_study_id>
    <secondary_id>UCSD-HRPP-050275</secondary_id>
    <nct_id>NCT00415298</nct_id>
  </id_info>
  <brief_title>AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer</brief_title>
  <official_title>AP5346 for Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck: A Pilot Study With Clinical and Biological Endpoints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as AP5346 and oxaliplatin, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying the dose of AP5346 to see how well it&#xD;
      works compared with the dose of oxaliplatin in treating patients with metastatic and/or&#xD;
      unresectable recurrent head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the delivered-dose of platinum per gram of wet weight from a single dose of&#xD;
           AP5346 vs a single dose of oxaliplatin in patients with metastatic and/or unresectable&#xD;
           recurrent squamous cell carcinoma of the head and neck (SCCHN).&#xD;
&#xD;
        -  Correlate platinum accumulation in the tumor and tumor DNA with clinical response in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Correlate platinum accumulation in the tumor and tumor DNA with molecular tumor response&#xD;
           as determined by GADD153 expression in patients treated with these regimens.&#xD;
&#xD;
        -  Quantify, by immunohistochemistry, the expression of the copper transporters CTR1,&#xD;
           ATP7A, and ATP7B in SCCHN tumors and correlate expression of these transporters with&#xD;
           tumor platinum levels.&#xD;
&#xD;
        -  Determine response in patients treated with AP5346.&#xD;
&#xD;
        -  Obtain additional data on the safety of AP5346 in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive AP5346 IV over 2 hours three times daily on days 1 and 15.&#xD;
&#xD;
        -  Arm II: Patients receive a single dose of unmodified oxaliplatin IV over 2 hours on day&#xD;
           1.&#xD;
&#xD;
      Beginning on day 29, all patients may receive AP5346 as in arm I. Treatment repeats every 28&#xD;
      days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo tumor biopsy before and 24 hours after the first course of treatment for&#xD;
      correlative pharmacological, immunohistochemical (IHC), and molecular studies. Tumor&#xD;
      specimens are assessed for platinum content, GADD153 gene expression (by molecular analysis),&#xD;
      and copper transporter (CTR1, ATP7A, ATP7B) expression by IHC.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Delivered-dose of platinum 24 hours after IV injection of a single dose of AP5346 vs a single dose of oxaliplatin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of platinum accumulation in the tumor and tumor DNA with clinical response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of platinum accumulation in the tumor and tumor DNA with molecular response as determined by GADD153 expression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of expression of CTR1, ATP7A, and ATP7B in squamous cell carcinoma of the head and neck (SCCHN) tumors by immunohistochemistry</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of expression of CTR1, ATP7A, and ATP7B in SCCHN tumors with tumor platinum levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of AP5346</measure>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DACH polymer platinate AP5346</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed primary squamous cell carcinoma of the head&#xD;
             and neck, including the oral cavity, oropharynx, hypopharynx, larynx, or nasopharynx&#xD;
&#xD;
               -  Metastatic and/or unresectable locally recurrent disease for which no curative&#xD;
                  treatment is available&#xD;
&#xD;
                    -  Patients must not be candidates for surgical resection or radiotherapy with&#xD;
                       curative intent&#xD;
&#xD;
                    -  Histological documentation of relapse required, especially for locoregional&#xD;
                       recurrence or recurrence in a previously irradiated field&#xD;
&#xD;
          -  Tumor(s) must be amenable to minimally invasive biopsy during the first course of&#xD;
             treatment&#xD;
&#xD;
               -  Must have evidence of progression or appearance of a new lesion after completion&#xD;
                  of radiotherapy, if biopsy site is in a previously irradiated field&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper level of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase (AP) ≤ 5 times normal (unless elevation is due to bone disease or&#xD;
             bone metastasis in the absence of liver disease)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN&#xD;
&#xD;
               -  AST and ALT &gt; 3 times ULN allowed provided AP ≤ 3 times ULN&#xD;
&#xD;
          -  Blood urea &lt; 1.5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR creatinine clearance &gt; 60 mL/min OR creatinine clearance&#xD;
             by 24-hour urine collection normal&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
          -  No history of hypersensitivity reactions of any kind to cisplatin or carboplatin&#xD;
&#xD;
          -  No other serious medical condition or psychiatric illness that would preclude the&#xD;
             patient's ability to give informed consent or receive study treatment&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No need for IV alimentation&#xD;
&#xD;
          -  No other serious illness or medical condition, including, but not limited to, the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris or cardiac arrhythmia&#xD;
&#xD;
               -  Significant neurologic or psychiatric disorders, including dementia or&#xD;
                  uncontrolled seizures&#xD;
&#xD;
               -  Hypophosphatemia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent anticancer treatment (i.e.,&#xD;
             chemotherapy, chemoradiotherapy, or radiotherapy)&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
               -  Prior cisplatin or carboplatin allowed&#xD;
&#xD;
          -  No concurrent anticoagulants other than cardioprotective doses of aspirin,&#xD;
             cyclooxygenase 1-inhibitory nonspecific anti-inflammatory drugs, or prophylactic&#xD;
             low-dose heparin&#xD;
&#xD;
          -  Concurrent bisphosphonates for hypercalcemia allowed provided the drug was initiated ≥&#xD;
             3 months prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L. Read, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

